Data / Drug companies / Lifestar Pharma LLC
Lifestar Pharma LLC: 159 products in the FDA NDC directory, labeler code 70756
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Lifestar Pharma LLC (labeler code 70756) lists 159 products in the FDA National Drug Code Directory, covering 58 finished drugs by generic name. By type: 159 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 1, 2026.
The request: Watch Lifestar Pharma LLC (FDA labeler code 70756): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70756
- Products in commercial distribution
- 159
- Packages
- 299
- Finished drugs by generic name
- 58
- Prescription products
- 159
- Over the counter products
- 0
- Flagged as original packager
- 135 of 135 products that carry the flag
- Started marketing in the last 12 months
- 27
- Products with a marketing end date set
- 2
- Earliest marketing start
- June 4, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 158 | 99.4% |
| New drug applications (NDA) | 1 | 0.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 159 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 52 | 32.7% |
| Injection, solution | 24 | 15.1% |
| Solution/ drops | 22 | 13.8% |
| Tablet, film coated | 18 | 11.3% |
| Capsule | 15 | 9.4% |
| Injection | 15 | 9.4% |
| Solution | 6 | 3.8% |
| Tablet, film coated, extended release | 2 | 1.3% |
| Capsule, delayed release | 2 | 1.3% |
| Capsule, liquid filled | 1 | 0.6% |
| Capsule, coated pellets | 1 | 0.6% |
| Tablet, extended release | 1 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Thiamine Hydrochloride | 70756-684 | Injection, solution | Generic drugs (ANDA) | October 1, 2026 |
| Rivaroxaban | 70756-006 | Tablet | Generic drugs (ANDA) | October 1, 2026 |
| Rosuvstatin | 70756-056 | Tablet, film coated | Generic drugs (ANDA) | August 16, 2026 |
| Rosuvstatin | 70756-055 | Tablet, film coated | Generic drugs (ANDA) | August 16, 2026 |
| Rosuvstatin | 70756-054 | Tablet, film coated | Generic drugs (ANDA) | August 16, 2026 |
| Rosuvstatin | 70756-053 | Tablet, film coated | Generic drugs (ANDA) | August 16, 2026 |
| Brimonidine Tartrate Ophthalmic Solution | 70756-679 | Solution/ drops | Generic drugs (ANDA) | June 1, 2026 |
| Brimonidine Tartrate Ophthalmic Solution | 70756-678 | Solution/ drops | Generic drugs (ANDA) | June 1, 2026 |
| Brimonidine Tartrate Ophthalmic Solution | 70756-677 | Solution/ drops | Generic drugs (ANDA) | June 1, 2026 |
| BUPROPION HCl ER (XL) | 70756-830 | Tablet, extended release | New drug applications (NDA) | May 1, 2026 |
| Cyanocobalamin | 70756-637 | Injection, solution | Generic drugs (ANDA) | May 1, 2026 |
| Bimatoprost | 70756-628 | Solution/ drops | Generic drugs (ANDA) | March 17, 2026 |
| Bimatoprost | 70756-627 | Solution/ drops | Generic drugs (ANDA) | March 17, 2026 |
| Bimatoprost | 70756-626 | Solution/ drops | Generic drugs (ANDA) | March 17, 2026 |
| Latanoprost Ophthalmic Solution | 70756-680 | Solution/ drops | Generic drugs (ANDA) | March 1, 2026 |
| Nicardipine hydrochloride | 70756-686 | Injection | Generic drugs (ANDA) | February 24, 2026 |
| Naloxone hydrochloride | 70756-850 | Injection, solution | Generic drugs (ANDA) | February 19, 2026 |
| Ticagrelor | 70756-048 | Tablet, film coated | Generic drugs (ANDA) | February 6, 2026 |
| Ticagrelor | 70756-047 | Tablet, film coated | Generic drugs (ANDA) | February 6, 2026 |
| Propranolol hydrochloride | 70756-298 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Propranolol hydrochloride | 70756-297 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Propranolol hydrochloride | 70756-296 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Propranolol hydrochloride | 70756-095 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Propranolol hydrochloride | 70756-094 | Tablet | Generic drugs (ANDA) | January 27, 2026 |
| Telmisartan and hydrochlorothiazide | 70756-317 | Tablet | Generic drugs (ANDA) | December 25, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.